The Center for Breakthrough Medicines at Discovery Labs Appoints Matthew Snyder as Associate Director, Engineering & Facilities
The Center for Breakthrough Medicines at Discovery Labs, an ecosystem accelerating the path to commercialization for cell and gene therapy companies, has appointed Matthew Snyder to the role of Associate Director, Engineering & Facilities. Mr. Snyder will be responsible for establishing the critical support services necessary for laboratory and manufacturing operations. These include setup of a comprehensive safety program; implementation of equipment tracking and maintenance and calibration management systems; interface coordination between site infrastructure utilities, building monitoring and process control systems; and technical engineering support for process operations and facility design.
“The extensive operational experience that Matt brings to The Discovery Labs, combined with his long history at the King of Prussia campus, was appealing to us and will benefit the CDMO as we put the critical support services and technical programs in place,” said Audrey Greenberg, Executive Director. “Matt’s background of engagement and active promotion of the life sciences market here in the Philadelphia region brings relationships and practical knowledge that will further benefit the company and our clients.”
Mr. Snyder brings extensive biopharma operations subject matter expertise, facilities startup, process engineering, and project management knowledge to this role at the Discovery Labs. He joins the Discovery Labs from CRB Consulting Engineers, where he led engineering design projects with specific focus on biopharmaceutical and advanced technology facilities and operations in his role as Senior Project Manager.
“This is an exciting time for Greater Philadelphia and the Cellicon valley with the constant emergence of biotech and ATMP companies focusing on the science of their therapeutic products but experiencing challenges along the road to commercialization. My focus at the Discovery Labs is to remove those barriers, provide the qualified services, laboratories, facilities, and processes to deliver the types of capabilities these companies need to progress therapy development, manufacture their product or provide a place to land and collaborate with other peers facing the same challenges. That’s the “What” that I do. Why I do it is to help bring life-changing and life-saving treatments to underserved patient populations and those suffering from a rare disease,” said Mr. Snyder.
Mr. Snyder has 25 years of biopharmaceutical industry experience with multiple operating companies, beginning in the co-op program at Drexel University and graduating in 1996 with a B.S. in Chemical Engineering. He has also served as President of the Delaware Valley Chapter of ISPE and remains an active and engaged member of the industry professional society.
About The Discovery Labs and The Center for Breakthrough Medicines
The Discovery Labs is a global platform company enabling the progression of life-changing and lifesaving therapies from idea to patient by providing CDMO services and life science real estate through our three subsidiaries: The Center for Breakthrough Medicines; The Discovery Labs Property Company; and our incubator, Unite IQ.
The Center for Breakthrough Medicines is the most comprehensive cell and gene therapy focused contract development and manufacturing organization in the world. CBM follows a molecule from idea to commercialization through an end-to-end solution including preclinical R&D, toxicology studies, IND writing, process development, plasmid production, viral vector production, cell therapy, clinical manufacturing, BLA support and commercial manufacturing.
The Discovery Labs Property Company builds best in class life science ecosystems catering to the biopharma industry’s R&D and manufacturing needs thereby enhancing speed to market and unique drug discovery.
The Discovery Labs incubator, Unite IQ provides space, services, equipment, and programming for life science startups. Discovery Labs Op Co/ Prop Co strategy offers tremendous scale thus accommodating customer needs to expand in place through both “buy and build” strategies. Sites are based in biotech centers of scientific influence with access to an abundance of talent and world leading research and development institutions, healthcare systems, universities, startup biotechs and large pharmaceutical enterprises. Our flagship site in King of Prussia is just minutes from University City where cell and gene therapy was pioneered, 20 minutes to Philadelphia International Airport and in the epicenter of the Commonwealth of Pennsylvania’s finest school districts and talent pool. https://breakthroughmedicines.com/
Latest posts by BioBuzz Media (see all)
- Matan Signs Deal with Ellume for Two Full Buildings at Progress Labs at Center 85 - May 11, 2021
- Adaptive Phage Therapeutics Announces $40.75 Million Series B Financing - May 11, 2021
- Gaithersburg’s Novavax Announces Positive Preclinical Data for Combination Influenza and COVID-19 Vaccine Candidate - May 10, 2021
- Global Biotech Company, Ellume, to Open Manufacturing Facility in Frederick - May 10, 2021
- Maryland Stem Cell Research Commission Announces over $6 Million in Awards to Accelerate Cures - May 10, 2021